US Patent 11,234,954: Doxepin Insomnia Claims, Patent Scope, Expiration Risk, and Competitive Landscape

US Patent 11,234,954 protects a patient-selection and dose-escalation protocol for low-dose doxepin in insomnia. Its central distinction is age-based dosing: 6 mg for adults ages 18 to 64 and an initial 3 mg dose for patients age 65 or older, with escalation to 6 mg only when needed. The patent does not claim doxepin as a molecule. It claims a clinical treatment method combining age, insomnia characteristics, susceptibility to adverse effects, dose, treatment duration, clinical assessment, and specified sleep-outcome findings.

The patent creates potential method-of-use exposure for prescribing, recommending, documenting, or implementing the claimed regimen. It does not prevent all generic doxepin products from entering the market. Generic risk depends on Orange Book listings, the approved label, prescribing behavior, induced-infringement evidence, and the validity and enforceability of the claims.

What does US Patent 11,234,954 cover?

The patent covers methods of treating insomnia with 3 mg or 6 mg doxepin, including Silenor or a pharmaceutically acceptable salt of doxepin.

Claim group	Principal subject matter	Key limitations
Claim 1	Age-differentiated treatment and conditional escalation	6 mg for ages 18-64; 3 mg initially for age 65 or older; escalation to 6 mg only if sleep improvement is inadequate; 3 mg for at least 15 consecutive days
Claim 2	Duration limitation	3 mg administered for at least 15 and up to 85 days
Claim 3	Separate age-based treatment method	6 mg for ages 18-64 and 3 mg for patients age 65 or older; 3 mg must reduce latency to persistent sleep
Claims 4-5	Duration limitations	At least 15 days and up to 85 days
Claim 6	Dose escalation	Evaluate response at 3 mg and increase to 6 mg if improvement is inadequate
Claims 7-10	Clinical distinctions	3 mg is ineffective for LPS in younger adults; 3 mg is effective for LPS in elderly patients; no statistically significant next-day residual sedation for specified groups
Claims 11-17	Dependent clinical and adverse-effect limitations	LPS findings and specified nervous-system and psychiatric side effects
Claim 18	Chronic-insomnia regimen	3 mg for elderly patients for at least 15 consecutive days and up to 85 days

The independent claims are claims 1, 3, and 18. Claims 1 and 3 require treatment of two different patients. Claim 18 also requires identification of both an adult ages 18 to 64 and an elderly patient, although its operative treatment requirements focus on chronic insomnia and the elderly patient’s 3 mg regimen.

How broad are the independent claims?

The claims are narrower than a conventional product claim but broader than a claim limited to a specific tablet formulation.

Claim 1

Claim 1 requires:

A first adult patient between 18 and 64 years old.
A second patient at least 65 years old.
Both patients must need insomnia treatment.
The second patient must be susceptible to specified adverse effects from a sleep medication.
The younger patient receives 6 mg doxepin daily.
The elderly patient initially receives 3 mg daily.
The 3 mg dose must continue for at least 15 consecutive days.
The prescriber or treatment system evaluates whether the elderly patient improves.
Escalation to 6 mg occurs only if the desired improvement is not achieved.

The claim also recites recognition of clinical trial results involving wake time during sleep, wake after sleep onset, and next-day residual sedation. Those limitations may create disputes over whether they are substantive method steps or merely statements of clinical knowledge accompanying the administration steps.

Claim 3

Claim 3 is structurally simpler. It requires:

6 mg doxepin for an adult ages 18 to 64;
3 mg doxepin for a patient age 65 or older;
at least 15 days of 3 mg treatment; and
a statistically significant reduction in latency to persistent sleep in the elderly population.

Unlike claim 1, claim 3 does not require an initial-dose evaluation followed by conditional escalation. Claim 3 does, however, retain the requirement that the elderly patient be susceptible to one or more specified sleep-medication side effects.

Claim 18

Claim 18 is directed to chronic insomnia and requires 3 mg doxepin for the elderly patient for at least 15 consecutive days, with a maximum duration of 85 days. It also requires the stated LPS efficacy finding.

The "up to 85 days" limitation is commercially important. A regimen exceeding 85 days may fall outside claims 2, 5, and 18, although it could still implicate broader claims if every limitation of another claim is met.

What patient characteristics trigger potential infringement?

The principal patient-selection limitations are age and susceptibility to adverse effects.

The elderly patient must be at least 65 years old. The claims identify potential adverse effects across several categories:

nervous-system effects;
psychiatric effects;
respiratory effects;
skin effects;
musculoskeletal effects;
connective-tissue effects; and
central nervous system effects.

Claims 12 through 17 narrow the central-nervous-system and psychiatric categories. Examples include somnolence, headache, dizziness, lethargy, balance disorder, anxiety, confusion, and abnormal dreams.

The susceptibility requirement is a material limitation. A generic label stating that elderly patients may experience adverse effects does not necessarily establish that every elderly patient is "susceptible" within the meaning of the claims. Evidence may include the patient’s medical history, prior medication intolerance, age-related risk factors, concomitant medicines, documented fall risk, cognitive impairment, respiratory disease, or a prescriber’s treatment notes.

What dose and duration does the patent protect?

The patent centers on 3 mg and 6 mg daily doses of doxepin.

Patient population	Claimed dose	Treatment condition
Adults ages 18-64	6 mg daily	Treatment of insomnia
Patients age 65 or older	3 mg daily	Initial or continuing dose, depending on claim
Elderly patients with inadequate response	Increase to 6 mg	Claim 1 and claim 6 require evaluation before escalation
Elderly patients under claims 2, 5, and 18	3 mg daily	At least 15 consecutive days and no more than 85 days

The claims do not require a particular tablet strength, dosage form, excipient, release profile, brand, manufacturer, or administration time. A tablet, capsule, compounded product, or other pharmaceutical presentation could potentially satisfy the drug and dose limitations if it delivers the required amount of doxepin.

The claims also cover a pharmaceutically acceptable salt of doxepin. That language prevents a design-around based solely on using a conventional acceptable salt rather than the free form.

What clinical outcomes are incorporated into the claims?

The patent uses several sleep-study endpoints:

wake time during sleep, or WTDS;
wake after sleep onset, or WASO;
latency to persistent sleep, or LPS; and
next-day residual sedation.

The claims distinguish treatment effects by age:

Endpoint	18-64 population	Age 65 or older
WTDS	6 mg produces a statistically significant decrease	Not the principal claimed distinction
WASO	Not the principal claimed distinction	3 mg produces a statistically significant decrease
LPS	3 mg does not produce a statistically significant reduction under claim 7	3 mg produces a statistically significant reduction
Next-day residual sedation	6 mg has no statistically significant effect under claim 10	3 mg has no statistically significant effect under claim 9

These limitations create two different infringement issues. First, a clinical result may be a limitation that must be demonstrated in the relevant population. Second, the prescriber may not personally know the statistical result when prescribing the drug. Patent litigation would likely address whether the results define the treatment method, describe the intended patient population, or merely state the evidentiary basis for the regimen.

What is the patent’s likely infringement theory?

The strongest potential infringement theory is induced infringement rather than direct infringement by a drug manufacturer.

A generic manufacturer may face risk if its label, promotional material, dosing instructions, electronic prescribing content, or medical-information communications encourage:

3 mg doxepin as the starting dose for patients age 65 or older;
treatment for at least 15 days;
escalation to 6 mg after inadequate response; and
use in elderly patients with risks of somnolence, dizziness, confusion, abnormal dreams, or related adverse effects.

Direct method infringement generally requires performance of every claimed step. Claims 1 and 3 require treatment of two patients in different age groups. A single patient or single prescription would not satisfy the two-patient structure unless the claim is interpreted as requiring a common actor to carry out both treatment components.

The two-patient requirement may narrow direct-infringement exposure but does not eliminate induced-infringement risk. A manufacturer could be accused of encouraging physicians, pharmacies, health systems, or patients to perform the claimed regimen.

What is the FDA and Orange Book status of low-dose doxepin?

Silenor is an FDA-approved low-dose doxepin product for the treatment of insomnia characterized by difficulties with sleep maintenance. The FDA-approved strengths are 3 mg and 6 mg. The labeling identifies 3 mg as the recommended starting dose for elderly patients and permits an increase to 6 mg where clinically appropriate.[2]

The Orange Book separates approved drug products from patent rights. A listed patent may create a certification obligation for an abbreviated new drug application, but an unlisted or improperly listed method patent may not provide the same regulatory effect.

Regulatory issue	Relevance to US 11,234,954
Active ingredient	Doxepin
Product category	Low-dose insomnia treatment
Approved strengths	3 mg and 6 mg
Approved use	Insomnia characterized by difficulties with sleep maintenance
Likely ANDA pathway	Section 505(j)
Primary patent risk	Method-of-use and induced-infringement exposure
Formulation risk	Limited from the stated claims because no specific formulation is required
Label carve-out	Potentially important if patented method language is not required for the approved indication

The FDA label is central because it can either support or weaken an induced-infringement case. If the label recommends the same age-based dosing protocol, a generic applicant may have difficulty avoiding the patented method while maintaining a label for the same indication. A successful section viii carve-out could reduce risk only if the remaining label does not encourage the claimed treatment steps.

When does US Patent 11,234,954 expire?

US Patent 11,234,954 issued on February 1, 2022. Its enforceable term is governed by the effective U.S. nonprovisional filing date, applicable patent-term adjustment, any terminal disclaimer, and other USPTO term information rather than by the grant date alone.[1]

The claims provided do not establish the patent’s earliest priority date or patent-term-adjustment calculation. The expiration date therefore cannot be calculated accurately from the claim text alone. The controlling date is the expiration date shown in the USPTO patent file and applicable Orange Book listing.

The patent’s commercial value depends on whether its term extends beyond the principal low-dose doxepin patents and whether the patent is listed against the relevant approved product. A later-expiring method patent can continue to create litigation and settlement leverage even after earlier formulation or use patents expire.

What earlier patents protect Silenor and low-dose doxepin?

The low-dose doxepin estate generally falls into four categories:

Low-dose insomnia use patents

These patents cover doxepin at low doses for insomnia, particularly sleep-maintenance insomnia. They are closer to the commercial indication for Silenor than older patents covering tricyclic antidepressant use.

Doxepin formulation patents

Formulation claims may cover:

3 mg or 6 mg solid dosage forms;
tablet composition;
dissolution or release characteristics;
content uniformity at low drug loading; and
stability or manufacturing parameters.

US 11,234,954 does not require any of these features. A formulation patent and the ’954 patent could be infringed independently.

Method-of-use patents

The ’954 patent is principally a method-of-use patent. Its distinguishing features are patient age, adverse-effect susceptibility, dosing sequence, duration, and clinical response.

Manufacturing and process patents

Manufacturing patents may cover low-dose blending, granulation, compression, coating, impurity control, or production of doxepin salts. These rights are separate from the treatment method and may create supply-chain exposure even if a generic manufacturer avoids the claimed patient regimen.

How strong is the patent estate for the claimed regimen?

The estate is strongest against a label that reproduces the patented dosing logic. It is weaker against products sold without encouragement of the patented method or against prescriptions that omit one or more patient-selection limitations.

Strength factor	Assessment
Clear commercial regimen	Strong
Alignment with FDA labeling	Potentially strong for induced infringement
Composition-of-matter protection	None apparent from the claims
Formulation protection	None apparent from the claims
Patient-specific limitations	Narrows claim scope
Two-patient structure in claims 1 and 3	Creates direct-infringement complexity
Statistical efficacy limitations	Creates claim-construction and proof issues
15- to 85-day duration	Provides a defined regimen but permits duration-based design-arounds
Older underlying molecule	Weak against independent generic development, stronger for label-based enforcement

Validity challenges could focus on obviousness, written description, enablement, indefiniteness, and whether the claimed treatment differences were adequately supported by the clinical data. The age-based selection and 3 mg-to-6 mg escalation may be challenged as an obvious application of known Silenor labeling and geriatric dosing principles. The patentee would rely on the claimed statistical differences in LPS, WASO, WTDS, and residual sedation to distinguish the regimen from routine dose selection.

Which companies could challenge the patent?

The most relevant challengers are manufacturers seeking approval for generic doxepin tablets or capsules, including companies developing abbreviated applications for 3 mg and 6 mg products. Potential challengers would typically include established generic manufacturers and specialty pharmaceutical companies with doxepin development programs.

A Paragraph IV challenge could assert that the patent is:

invalid;
not infringed;
unenforceable; or
not properly listed for the proposed product or indication.

The claim limitations create several possible non-infringement positions:

The proposed label does not identify patients susceptible to the specified adverse effects.
The label does not require treatment for at least 15 consecutive days.
The label does not require evaluation before escalation.
The label omits the elderly-patient 3 mg-to-6 mg sequence.
The proposed product is not indicated for sleep-maintenance insomnia.
The label uses a section viii carve-out for the patented method.

The practical outcome depends on whether the FDA-approved generic label necessarily directs the claimed regimen. A product that is technically capable of being used in the patented manner is not automatically infringing.

Does the patent create biosimilar risk?

No. Biosimilar procedures do not apply because doxepin is a small-molecule drug, not a biologic subject to the Public Health Service Act. The relevant pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k).

The competitive risk is therefore generic-drug entry, patent certification, label carving, and possible Hatch-Waxman litigation.

How does doxepin compare with competing insomnia drugs?

Drug	Mechanism or class	Main commercial distinction	Patent-entry issue
Low-dose doxepin	Histamine H1 antagonism at low dose	Sleep-maintenance insomnia; 3 mg and 6 mg dosing	Generic and method-of-use exposure
Zolpidem	GABA-A receptor modulator	Broad use across insomnia formulations	Mature generic competition
Eszopiclone	Cyclopyrrolone hypnotic	Sleep onset and maintenance	Mature generic competition
Ramelteon	Melatonin receptor agonist	Sleep-onset insomnia	Generic competition
Suvorexant	Dual orexin receptor antagonist	Sleep onset and maintenance	Branded patent estate and ANDA challenges
Lemborexant	Dual orexin receptor antagonist	Sleep onset and maintenance	Branded patent estate
Daridorexant	Dual orexin receptor antagonist	Sleep onset and maintenance	Later-generation patent estate

Doxepin’s competitive advantage is its low-dose positioning and lack of controlled-substance scheduling in the United States. Its commercial disadvantage is the age of the active ingredient and the availability of generic antidepressant-dose doxepin, although high-dose antidepressant products are not direct substitutes for the low-dose insomnia regimen.

What generic launch scenarios are most likely?

Scenario 1: Full-label generic launch

A generic applicant retains the full sleep-maintenance indication and age-based dosing instructions. This creates the highest induced-infringement risk if the label mirrors the patented regimen.

Scenario 2: Section viii carve-out

The applicant removes or narrows patented method language while retaining non-patented uses. This may reduce infringement exposure but can weaken the commercial value of the product if sleep-maintenance insomnia is the principal approved use.

Scenario 3: Paragraph IV litigation

The applicant challenges validity or infringement and seeks a 180-day first-filer period if eligible. The principal disputes would likely involve obviousness, claim construction, the two-patient limitations, statistical-result limitations, and whether the proposed label induces the claimed method.

Scenario 4: Settlement

A settlement could establish a licensed entry date, label restrictions, or supply arrangements. The commercial value of any settlement would depend on the remaining patent term, Orange Book listing status, and the ability of other generic applicants to enter independently.

What litigation and licensing issues matter?

A current litigation conclusion cannot be drawn from the claims alone. The critical public-record checks are the USPTO assignment history, Orange Book patent listing, district-court docket history, Patent Trial and Appeal Board proceedings, and any settlement filing under the Medicare Modernization Act.

Licensing analysis should focus on:

ownership and assignment history from the original low-dose doxepin developer;
rights transferred with the Silenor product;
exclusive versus nonexclusive method-of-use rights;
sublicensing rights;
geographic scope;
royalty obligations;
rights to enforce against ANDA applicants; and
termination provisions tied to patent invalidity or expiration.

The relevant geographic protection is U.S.-only for US 11,234,954. Foreign counterparts must be assessed separately by country, including national-phase status, granted claims, prosecution amendments, and local patent-term calculations.

Key Takeaways

US 11,234,954 is a method-of-treatment patent for age-specific low-dose doxepin use in insomnia.
The central regimen is 6 mg for adults ages 18 to 64 and 3 mg initially for patients age 65 or older.
Claims 1, 3, and 18 are the principal enforcement claims.
The patent requires combinations of age, insomnia treatment, adverse-effect susceptibility, dose, clinical response, and treatment duration.
Claims 2, 5, and 18 limit the elderly 3 mg regimen to at least 15 and up to 85 days.
The patent does not claim doxepin’s chemical structure or a specific tablet formulation.
Generic risk is primarily a method-of-use and induced-infringement issue.
The two-patient structure in claims 1 and 3 may complicate direct-infringement theories.
The FDA label and Orange Book listing determine whether an ANDA applicant can practically avoid the claimed method.
Doxepin is a small molecule, so biosimilar law is not relevant.
The patent expiration date must be taken from the USPTO term record and any applicable Orange Book entry because the claim text does not identify the priority or term-adjustment data.

FAQs About US Patent 11,234,954

Can a generic manufacturer sell 3 mg doxepin without infringing US Patent 11,234,954?

Yes, potentially. Sale of the product alone does not establish infringement of every claimed method. Risk increases if the generic label directs elderly patients to use 3 mg for at least 15 days, identifies the relevant adverse-effect population, and supports escalation to 6 mg.

Does the patent cover all elderly-patient use of doxepin?

No. The claims require additional limitations, including insomnia treatment, specified dose levels, adverse-effect susceptibility, clinical outcome limitations, and, for certain claims, a defined treatment duration.

Is a 6 mg doxepin product covered by the patent?

A 6 mg product may be used in a patented regimen, particularly for adults ages 18 to 64 or as an escalation dose for elderly patients. The claims do not create a standalone composition claim to every 6 mg doxepin product.

Can a manufacturer design around the 15-day treatment limitation?

Potentially. A regimen that does not require at least 15 consecutive days may avoid claims containing that limitation, but other claims must be analyzed separately. A duration change alone does not avoid a claim lacking the same duration requirement.

Does US Patent 11,234,954 block doxepin use for depression?

No. The claims are directed to insomnia treatment. They do not claim doxepin treatment for depression or other psychiatric indications.

References

United States Patent and Trademark Office. (2022). U.S. Patent No. 11,234,954, Methods of treating insomnia.
U.S. Food and Drug Administration. (2023). Silenor (doxepin) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and section viii statements.
United States Code, 35 U.S.C. §§ 154, 271, and 282.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-001	Mar 17, 2010	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF INSOMNIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2687118	⤷ Start Trial
Canada	2687124	⤷ Start Trial
European Patent Office	2026792	⤷ Start Trial
Japan	2009537553	⤷ Start Trial
Japan	2009537554	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 11,234,954